insights_auto
Why is GRAL down 4.50%?
Dive Deeperchevron_right
GRAL:NASDAQ
Grail Inc
$115.89
arrow_downward
-4.50%(-5.46) 1D
$115.89
0.00% (0.00)
bedtimeAfter hours
Closed: Nov 13, 4:00:01 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GRAL...
Open
$121.95
High
$122.00
Low
$114.00
Mkt. cap
5.21B
Avg. vol.
969.33K
Volume
361.13K
52-wk high
$166.48
52-wk low
$41.50
EPS
-$9.50
Shares outstanding
44.96M
No. of employees
910
Open
$121.95
High
$122.00
Low
$114.00
Mkt. cap
5.21B
Avg. vol.
969.33K
Volume
361.13K
52-wk high
$166.48
52-wk low
$41.50
EPS
-$9.50
Shares outstanding
44.96M
No. of employees
910
News stories
From web sources and news partners
ING Sprinters
·
2 days ago
De AEX Index blijft voortmodderen
Nieuws.nl
·
1 day ago
AEX-index lager door onrust rond Nvidia
Trefis
·
35 minutes ago
30 S&P 500 Stocks Just Made New 52-Week Highs
Profile
GRAIL, Inc. is an American biotechnology company based in Menlo Park, California founded in 2015 seeking to develop an early cancer screening test for people who do not have symptoms. As a startup it was a subsidiary of Illumina, which bought it outright in 2021.
In June 2021, GRAIL launched their liquid biopsy, or multi-cancer early detection test, which they called Galleri test. In 2023, EU regulators ordered Grail to be spun-out from Illumina which was completed on June 24, 2024.
Joshua Ofman is CEO. Wikipedia
About Grail Inc
CEO-
Employees910
Founded2015
HeadquartersMenlo Park, California, United States
SectorHealth Care
IndustryBiotechnology
Websitegrail.com